United Therapeutics Management
Management Kriterienprüfungen 2/4
United Therapeutics CEO ist Martine Rothblatt , ernannt in Jan 1996, hat eine Amtszeit von 28.83 Jahren. Die jährliche Gesamtvergütung beträgt $16.96M , bestehend aus 8.7% Gehalt und 91.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 1.49% der Aktien des Unternehmens, im Wert von $251.39M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 15.6 Jahre bzw. 22.2 Jahre.
Wichtige Informationen
Martine Rothblatt
Geschäftsführender
US$17.0m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 8.7% |
| Amtszeit als Geschäftsführer | 28.8yrs |
| Eigentum des Geschäftsführers | 1.5% |
| Durchschnittliche Amtszeit des Managements | 15.6yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 22.2yrs |
Jüngste Management Updates
Recent updates
United Therapeutics: One To Believe In Despite Competitive Threats
Nov 14Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 18
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | n/a | n/a | US$1b |
| Mar 31 2024 | n/a | n/a | US$1b |
| Dec 31 2023 | US$17m | US$1m | US$985m |
| Sep 30 2023 | n/a | n/a | US$900m |
| Jun 30 2023 | n/a | n/a | US$872m |
| Mar 31 2023 | n/a | n/a | US$728m |
| Dec 31 2022 | US$5m | US$1m | US$727m |
| Sep 30 2022 | n/a | n/a | US$707m |
| Jun 30 2022 | n/a | n/a | US$631m |
| Mar 31 2022 | n/a | n/a | US$687m |
| Dec 31 2021 | US$4m | US$1m | US$476m |
| Sep 30 2021 | n/a | n/a | US$462m |
| Jun 30 2021 | n/a | n/a | US$471m |
| Mar 31 2021 | n/a | n/a | US$405m |
| Dec 31 2020 | US$5m | US$1m | US$515m |
| Sep 30 2020 | n/a | n/a | US$469m |
| Jun 30 2020 | n/a | n/a | US$430m |
| Mar 31 2020 | n/a | n/a | US$528m |
| Dec 31 2019 | US$46m | US$1m | -US$104m |
| Sep 30 2019 | n/a | n/a | -US$92m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$150m |
| Dec 31 2018 | US$16m | US$1m | US$589m |
| Sep 30 2018 | n/a | n/a | US$543m |
| Jun 30 2018 | n/a | n/a | US$713m |
| Mar 31 2018 | n/a | n/a | US$484m |
| Dec 31 2017 | US$37m | US$1m | US$418m |
Vergütung im Vergleich zum Markt: MartineDie Gesamtvergütung ($USD16.96M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD12.50M).
Entschädigung vs. Einkommen: MartineDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.
Geschäftsführer
Martine Rothblatt (69 yo)
28.8yrs
Amtszeit
US$16,958,057
Vergütung
Dr. Martine A. Rothblatt, Ph D., J.D., M.B.A., founded United Therapeutics Corporation in 1996 and has been its Chief Executive Officer since June 26, 2016 and as its Chairman since 1996. Dr. Rothblatt ser...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.49% $ 251.4m | |
| President & COO | 8.4yrs | US$9.81m | 0.0058% $ 971.1k | |
| CFO & Treasurer | 11.8yrs | US$6.05m | 0.018% $ 3.0m | |
| Executive VP | 28.8yrs | US$5.15m | 0.082% $ 13.8m | |
| Head of Investor Relations | no data | keine Daten | keine Daten | |
| Associate Vice President of Human Resources | no data | keine Daten | keine Daten | |
| Senior Vice President of Strategic Operations & Logistics | no data | keine Daten | keine Daten | |
| Executive VP of Technical Operations | 15.6yrs | keine Daten | keine Daten | |
| Executive Vice President of Product Development & Xenotransplantation | no data | keine Daten | keine Daten | |
| Senior VP & Chief Medical Officer | no data | keine Daten | keine Daten |
15.6yrs
Durchschnittliche Betriebszugehörigkeit
56yo
Durchschnittliches Alter
Erfahrenes Management: UTHRDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (15.6 ).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Founder | 28.8yrs | US$16.96m | 1.49% $ 251.4m | |
| Member of the Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Independent Director | 22.8yrs | US$457.60k | 0.027% $ 4.6m | |
| Independent Director & Member of the Scientific Advisory Board | 22.2yrs | US$471.54k | 0.029% $ 4.9m | |
| Independent Director & Member of the Scientific Advisory Board | 22.8yrs | US$456.54k | 0.0039% $ 659.8k | |
| Independent Vice Chairman & Lead Independent Director | 22.1yrs | US$532.60k | 0.0045% $ 754.0k | |
| Independent Director | 21.3yrs | US$481.54k | 0.0082% $ 1.4m | |
| Member of the Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Independent Director | 22.8yrs | US$456.54k | 0.050% $ 8.5m | |
| Member of the Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Independent Director | 9.4yrs | US$488.66k | 0.013% $ 2.1m | |
| Independent Director | 15.6yrs | US$513.66k | 0.039% $ 6.6m |
22.2yrs
Durchschnittliche Betriebszugehörigkeit
76yo
Durchschnittliches Alter
Erfahrener Vorstand: UTHRDie Vorstandsmitglieder sind sehr erfahren ( 22.2 ).